N‐terminally and C‐terminally truncated forms of glucose‐dependent insulinotropic polypeptide are high‐affinity competitive antagonists of the human GIP receptor
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Glucose‐dependent insulinotropic polypeptide (GIP) affects lipid, bone and glucose homeostasis. High‐affinity ligands for the GIP receptor are needed to elucidate the physiological functions and pharmacological potential of GIP in vivo. GIP(1–30)NH 2 is a naturally occurring truncation of GIP(1–42). Here, we have characterized eight N‐terminal truncations of human GIP(1–30)NH 2. Experimental Approach: COS‐7 cells were transiently transfected with human GIP receptors and assessed for cAMP accumulation upon ligand stimulation or competition binding with 125 I‐labelled GIP(1–42), GIP(1–30)NH 2, GIP(2–30)NH 2 or GIP(3–30)NH 2. Key Results: GIP(1–30)NH 2 displaced 125 I‐GIP(1–42) as effectively as GIP(1–42) (K i 0.75 nM), whereas the eight truncations displayed lower affinities (K i 2.3–347 nM) with highest affinities for GIP(3–30)NH 2 and GIP(5–30)NH 2 (5–30)NH 2. Only GIP(1–30)NH 2 (E max 100% of GIP(1–42)) and GIP(2–30)NH 2 (E max 20%) were agonists. GIP(2‐ to 9–30)NH 2 displayed antagonism (IC 50 12–450 nM) and Schild plot analyses identified GIP(3–30)NH 2 and GIP(5–30)NH 2 as competitive antagonists (K i 15 nM). GIP(3–30) NH 2 was a 26‐fold more potent antagonist than GIP(3–42). Binding studies with agonist (125 I‐GIP(1–30)NH 2), partial agonist (125 I‐GIP(2–30)NH 2) and competitive antagonist (125 I‐GIP(3–30)NH 2) revealed distinct receptor conformations for these three ligand classes. Conclusions and Implications: The N‐terminus is crucial for GIP agonist activity. Removal of the C‐terminus of the endogenous GIP(3–42) creates another naturally occurring, more potent, antagonist GIP(3–30)NH 2, which like GIP(5–30)NH 2, was a high‐affinity competitive antagonist. These peptides may be suitable tools for basic GIP research and future pharmacological interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“BJP British Journal ofPharmacology DOI:10.1111/bph.13384 www.brjpharmacol.org”
InfluentialPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 2×
“BJP British Journal ofPharmacology DOI:10.1111/bph.13384 www.brjpharmacol.org”
InfluentialSelf-citationNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 2×
“BJP British Journal ofPharmacology DOI:10.1111/bph.13384 www.brjpharmacol.org”
InfluentialGlucose-Dependent Insulinotropic Polypeptide
Christensen, M., Vedtofte, L., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2011) · Diabetes · doi:10.2337/db11-0979 · Cited by 353
Self-citationCirculation and Degradation of GIP and GLP-1
Deacon, C. F. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826160 · Cited by 299
Effect of GIP and GLP-1 antagonists on insulin release in the rat
Tseng, C.-C., Zhang, X.-Y., & Wolfe, M. M. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.276.6.e1049 · Cited by 95
Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP
Mentlein, R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.005 · Cited by 94 · cited 1×
“BJP British Journal ofPharmacology DOI:10.1111/bph.13384 www.brjpharmacol.org”
Influential
Cited by
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
“a modified GIPR antagonist, GIP(3-30)NH2 [45], in islets from GLP-1PR / mice).”
BackgroundThe incretin system in healthy humans: The role of GIP and GLP-1
Holst, J. J. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.014 · Cited by 248
Self-citationOptimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229
GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Holst, J. J., & Rosenkilde, M. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa327 · Cited by 207
“For GIP, an effective and potent receptor antagonist for human use was only recently introduced (24), but with these tools at hand, it was now possible to analyze the combined actions of GIP and GLP-1 in the same experiment.”
BackgroundSelf-citationGasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., et al. (2019) · Diabetes · doi:10.2337/db18-1123 · Cited by 193
Self-citation
Metadata
- Authors
- Hansen, L. S., Sparre‐Ulrich, A. H., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J., & Rosenkilde, M. M.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2016-01-30
- Volume
- 173
- Issue
- 5
- Pages
- 826-838
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2181214304
- Cited by
- 98
- References
- 9
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.